Objectives: We investigated the activity of BAL30072, a dihydroxypyridone monosulfactam, against carbapenem-resistant Enterobacteriaceae and non-fermenters (i) alone, (ii) combined with BAL29880 (to inhibit AmpC) and/or clavulanate [to inhibit extended-spectrum b-lactamases (ESBLs)] and (iii) combined 1 : 1 with meropenem.
Introduction
BAL30072 (Basilea Pharmaceutica International Ltd) is a dihydroxypyridone monosulfactam antibiotic, now entering Phase I. It inhibits most Gram-negative bacteria at low concentrations, though Gram-positive species are resistant, as they are to classical monobactams such as aztreonam. 1, 2 Unlike aztreonam, BAL30072 retains activity against most Enterobacteriaceae with CTX-M extended-spectrum b-lactamases (ESBLs), although its MICs are raised for many with TEM and (especially) SHV ESBLs or copious AmpC activity. 2 As a monocyclic b-lactam, BAL30072 is stable to metallo-carbapenemases; 2 it is also reported to remain active against Klebsiella pneumoniae with KPC carbapenemase unless an SHV-ESBL or AmpC activity is also present. 2 We investigated the activity of BAL30072 alone and combined with clavulanate (to inhibit ESBLs), with BAL29880 (to inhibit AmpC), and with meropenem: (i) against carbapenem-resistant Enterobacteriaceae; (ii) against Pseudomonas aeruginosa with carbapenemase-and non-carbapenemase-mediated resistance; and (iii) against Acinetobacter baumannii with OXA carbapenemases or metallo-carbapenemases.
Materials and methods

Isolates
The test panels (Table 1) were sourced from multiple UK hospitals to ensure epidemiological diversity. Carbapenemases were identified by PCR and sequencing; porin loss was demonstrated by outer membrane profiles and gene sequencing. 4, 5 Up-regulated efflux in P. aeruginosa was inferred on the basis of the absence of b-lactamase activity coupled with broad resistance to b-lactams (except imipenem) with MIC carbenicillin .MIC cefotaxime. MIC piperacillin/tazobactam.MIC ceftazidime, as is characteristic of the phenotype. A. baumannii isolates were identified by the presence of the bla OXA-51 -like gene. 6 
Antibiotics
BAL30072 and BAL29880 were from Basilea (Basel, Switzerland), meropenem from AstraZeneca (Macclesfield, UK), clavulanic acid from GlaxoSmithKline (Brentford, UK) and aztreonam, cefepime and colistin from Sigma (Poole, UK).
MIC determinations
MICs were determined by CLSI agar dilution 7 with inhibitors at 4 mg/L and with BAL30072 +meropenem tested as a 1 :1 combination. MICs are expressed relative to the BAL30072 concentration (i.e. an MIC of 4 mg/L means an MIC of 4+4 mg/L). In order to induce iron-uptake pathways, which BAL30072 may exploit, 2,2 ′ -bipyridyl was included at 16 mg/L in all tests for BAL30072 and its combinations.
1,2
Results MIC distributions are shown in Table 2 , with summary parameters in Table 3 , which uses current CLSI breakpoints for marketed agents and an arbitrary cut-off at 4 mg/L for BAL30072 and its combinations.
Carbapenem-resistant Enterobacteriaceae
None of the carbapenem-resistant Enterobacteriaceae groups was consistently resistant to BAL30072 at 1 mg/L, whereas most were resistant to meropenem and cefepime at current CLSI or EUCAST breakpoints; aztreonam resistance was universal except among those with metallo-b-lactamases (MBLs) ( Tables 2  and 3 ). Nevertheless, MICs of BAL30072 were widely scattered within each group so that values for the most susceptible isolates clustered around 0.06-0.5 mg/L whilst those for the least susceptible were ≥32 mg/L. This scatter implies that any resistance depended on other mechanisms besides carbapenemase, and this view is supported by the fact that resistance was often reversed by addition of clavulanate and/or BAL29880 as inhibitors of ESBL and AmpC activity, respectively (Table 3) .
Overall, 69% of the carbapenem-resistant Enterobacteriaceae isolates were susceptible to BAL30072 alone, rising to 77% with either clavulanate or BAL29880 added, and to 89% with both inhibitors present. The only group where ,90% of isolates were susceptible to BAL30072+ BAL29880 + clavulanate were those with KPC carbapenemases, where 6/15 (40%) remained resistant. These resistant organisms belonged to the international K. pneumoniae sequence type (ST) 258 lineage, 8 which frequently co-produces an SHV-11 or -12 ESBL together with its KPC-2 or -3 carbapenemase. 9, 10 Among the 46 Enterobacteriaceae with MBLs (16 with NDM and 15 each with VIM and IMP enzymes), 21 (11 with IMP and 5 each with NDM or VIM) were susceptible to aztreonam at 4 mg/L, suggesting the absence of ESBL or AmpC activity. MICs of BAL30072 for these aztreonam-susceptible isolates ranged from 0.03 to 16 mg/L, with only one value (for an Enterobacter cloacae isolate with a VIM enzyme) .4 mg/L. Moreover, only 5 of these 21 aztreonam-susceptible MBL producers showed ≥8-fold potentiation of BAL30072 even with both inhibitors added, supporting the lack of significant ESBL or AmpC activity. By contrast, 25 of the MBL-producing Enterobacteriaceae (4 with IMP, 10 with VIM and 11 with NDM enzymes) were nonsusceptible to aztreonam, with MICs .4 mg/L, and for these the MICs of BAL30072 ranged from 0.06 to .128 mg/L, with 11/25 values .4 mg/L. Addition of both clavulanate and BAL29880 gave ≥8-fold potentiation on BAL30072 against 20 of these 25 aztreonam-resistant organisms. Only two (a single K. pneumoniae Carbapenem-resistant P. aeruginosa BAL30072 was consistently active at 4 mg/L (with MICs mostly 0.25-2 mg/L) against OprD-deficient P. aeruginosa resistant only to carbapenems. This activity was not increased by addition of either b-lactamase inhibitor, whereas BAL30072+ meropenem was consistently more active than BAL30072 alone, with MICs in the range 0.06 -0.25 mg/L. Reasons for this potentiation are unclear.
The activity of all compounds except colistin was impaired against P. aeruginosa isolates with phenotypes suggesting efflux type resistance. MIC values for BAL30072 ranged from 1 to 32 mg/L with little clustering; 8/12 values were ≤4 mg/L compared with none ≤8 mg/L (the CLSI breakpoint) for aztreonam. MICs of BAL30072 for the P. aeruginosa isolates with VIM and IMP metallo-enzymes ranged from 0.06 to 32 mg/L, with 19/25 values ≤4 mg/L and little potentiation by inhibitors or meropenem. This activity was substantially better than that of aztreonam, where just 4/25 isolates were susceptible at 8 mg/L and none at 4 mg/L.
Carbapenem-resistant A. baumannii
The carbapenem-resistant A. baumannii isolates (which variously had OXA or NDM carbapenemases) were consistently resistant to aztreonam, cefepime and meropenem, whereas MICs of BAL30072 were mostly scattered between 0.25 and 16 mg/L for isolates with NDM, OXA-23, -24 and -51 carbapenemases, though with values .128 mg/L for 9/11 with OXA-58 enzyme. The addition of inhibitors had little effect regardless of enzyme type and, although many isolates with OXA-58 were less resistant to BAL30072 + meropenem than to BAL30072 alone, the MIC values of 16-32 mg/L corresponded, within a dilution, to those of meropenem by itself.
Discussion
This study, like others, 1, 2 shows that BAL30072 has promising activity against many otherwise extremely resistant carbapenemase producers, but that its behaviour is complex and is modulated by other mechanisms present in some strains. These observations, and the synergy seen for some strains with clavulanate and BAL29880, are compatible with the view that BAL30072 (i) evades KPC carbapenemases, OXA-48 carbapenemases and metallo-carbapenemases, but is vulnerable to AmpC and TEM and SHV (not CTX-M) ESBLs, with resistance arising when any of these enzymes is expressed copiously, and (ii) has unusual uptake and accumulation properties, which may vary among strains. 2 When tested alone, BAL30072 was active against 69% of carbapenem-resistant Enterobacteriaceae at 4 mg/L, with this proportion increased to 89% if both clavulanate and BAL30072 were added. Of the 10/91 Enterobacteriaceae that remained resistant to BAL30072 + BAL29880 + clavulanate at 4 +4 + 4 mg/L, six were K. pneumoniae belonging to the international ST258 lineage, which typically also produces an SHV-11 or -12 ESBL. 9 -11 Although clavulanate inhibits SHV ESBLs, 12 it is plausible either: (i) that the quantity of enzyme overwhelmed the inhibitor; or (ii) that clavulanate is hydrolysed by KPC enzymes, as described by Papp-Wallace et al., 13 and that this precludes effective inhibition. This weakness is concerning insofar as the ST258-KPC lineage is widespread in North and South America, Asia, Europe and Israel. 7, 14 If hydrolysis of clavulanate is the explanation, the problem might be overcome with a less vulnerable inhibitor, though KPC enzymes reportedly also hydrolyse penicillanic acid sulphones such as sulbactam and tazobactam. 13 Unsurprisingly, BAL30072 retained full activity against P. aeruginosa isolates that owed carbapenem resistance to loss of OprD, a mechanism that does not affect other b-lactams, which do not use this porin. Activity was impaired versus some isolates with phenotypes implying up-regulated efflux, with MICs of 16-32 mg/L for 4/12 isolates. Nevertheless, BAL30072 Mushtaq et al.
was more active than meropenem, aztreonam or cefepime against these organisms. Activity was also good against most P. aeruginosa with VIM and IMP MBLs, with 19/25 isolates susceptible at 4 mg/L; although aztreonam also approaches stability to MBLs, many MBL-positive P. aeruginosa are resistant owing to AmpC or efflux activity. As found in other studies, 1,2,15,16 BAL30072 had good activity against many carbapenemase-producing Acinetobacter, but with occasional exceptions, most of them producing OXA-58 carbapenemase. The 11 OXA-58-positive isolates were from at least seven centres and represented at least five clones, discounting their being replicates; nevertheless, a specific association between OXA-58 enzyme and resistance is refuted by our previous results 1 and by those of a larger study by Higgins et al. 16 Many of the MICs (range 0.25 -16 mg/L, with 6/10 values from 4 to 16 mg/L) for A. baumannii with OXA-23 carbapenemase also were higher than found previously (126/143 values 0.25-2 mg/L) for a large collection of isolates of the OXA-23 clone 1, 1 which is prevalent in UK ICUs. 17 It seems likely that the susceptibility or otherwise of A. baumannii with OXA enzymes reflects other clone-related factors, not carbapenemase type per se.
BAL30072 + meropenem achieved small gains in activity compared with BAL30072 alone against individual Enterobacteriaceae and non-fermenter isolates, but there was no clear pattern except for a consistent gain in activity against P. aeruginosa with carbapenem resistance owing to loss of OprD.
Overall, these data show that BAL30072 has a substantial capacity to overcome carbapenem resistance in Gram-negative bacteria, including much of that mediated by carbapenemases. This potential can be expanded by combination with b-lactamase inhibitors, though comprehensive activity was not achieved.
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